A Booster Dose of Inactivated Vaccine (Vero Cell) Against EV71 in Chinese Children

Summary

Hand, foot, and mouth disease (HFMD) is a common viral illness in infants and children caused by viruses that belong to the enterovirus genus of the picornavirus family. Although most HFMD cases do not result in serious complications, outbreaks of HFMD caused by enterovirus 71 (EV71) can present with a high rate of neurological complications, including meningoencephalitis, pulmonary complications, and can even cause infant death. HFMD caused by EV71 has become a major emerging infectious disease in Asia and the highly pathogenic potential of EV71 clearly requires the attention of world medical community.

The phase II study of inactivated vaccine (vero cell) against EV71 has completed last month in Jiangsu Province in China. The data from the phase II study suggested that the inactivated EV71 vaccine had a clinically acceptable safety and good immunogenicity for healthy Chinese children and infants. But the antibody titer against EV71 was found decreased significantly at month 8 compared to that at day 56. Considering the similar dynamic trend had also been found in the antibody against poliovirus induced by polio vaccines, and whose immunization schedule contains a booster dose administrated at 1 to 1.5 year after the first 3 doses of fundamental immunity. In order to find a better immunization schedule for children, the investigators decided to perform this booster immunity trial among these children who had received two doses of EV71 vaccines (around one year after the fundamental immunity). The investigators do the recruitment among these children who had participated in the previous phase II trial and received EV71 vaccines, and randomize them in a ratio of 2:1 to receive either a booster dose of EV71 vaccines or placebo.

Conditions

• EV71-associated Disease

Interventions

BIOLOGICAL

alum-adjuvant 160U /0.5ml

inactivated vaccine (vero cell) alum-adjuvant 160U /0.5ml EV71 vaccine

BIOLOGICAL

alum-adjuvant 320U /0.5ml

inactivated vaccine (vero cell) alum-adjuvant 320U /0.5ml EV71 vaccine

BIOLOGICAL

alum-adjuvant 640U /0.5ml

inactivated vaccine (vero cell) alum-adjuvant 640U /0.5ml EV71 vaccine

BIOLOGICAL

adjuvant-free 640U /0.5ml

inactivated vaccine (vero cell) adjuvant-free 640U /0.5ml EV71 vaccine

BIOLOGICAL

0/0.5ml placebo

0/0.5ml placebo

Sponsors & Collaborators

• Bejing Vigoo Biological Co., LTD

  collaborator INDUSTRY

• Jiangsu Province Centers for Disease Control and Prevention

  lead NETWORK

Study Design

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

TRIPLE

Model

PARALLEL

Eligibility

Min Age

21 Months

Max Age

51 Months

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2012-11-30

Primary Completion

2013-01-31

Completion

2013-02-28

Countries

• China

Study Locations